Literature DB >> 8799580

Prevention by the 5-HT3 receptor antagonist, ondansetron, of morphine-dependence and tolerance in the rat.

S C Hui1, E L Sevilla, C W Ogle.   

Abstract

1. The effect of ondansetron, a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist, was studied in morphine-addicted rats. Morphine-dependence and tolerance, induced by drinking increasing concentrations of morphine sulphate in 5% sucrose solution for 3 weeks, were demonstrated by the naloxone-precipitated withdrawal syndrome and tail flick response to a thermal noxious stimulus (water at 50 degrees C), respectively. 2. Morphine-dependence, assessed by naloxone precipitated withdrawal, was undetectable by the 6th day, when the animals drank only tap water for 7 days after the 3-week induction period. 3. When detoxified rats were offered sucrose and morphine solutions for 10 days, the recurrence of opiate solution preference with relapse to dependence and tolerance was observed. 4. Giving ondansetron (0.1 or 1 microgram kg-1; i.p.; twice daily) on the 14th day of, or 7 days prior to, the 3-week induction period reduced dependence and tolerance seen during the 3-week morphine induction and the 10-day drinking preference periods. 5. 5-Hydroxytryptamine2 (5-HT2) receptor antagonism by cyproheptadine (100 or 250 micrograms kg-1; i.p.; twice daily) did not influence morphine-dependence and tolerance. 6. These findings suggest that ondansetron may be useful for treating opiate addiction and lowering the recidivism rate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799580      PMCID: PMC1909532          DOI: 10.1111/j.1476-5381.1996.tb15504.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  The effects of ondansetron (GR38032F) in rats and mice treated subchronically with diazepam.

Authors:  B Costall; B J Jones; M E Kelly; R J Naylor; N R Oakley; E S Onaivi; M B Tyers
Journal:  Pharmacol Biochem Behav       Date:  1989-12       Impact factor: 3.533

2.  Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain.

Authors:  R M Hagan; A Butler; J M Hill; C C Jordan; S J Ireland; M B Tyers
Journal:  Eur J Pharmacol       Date:  1987-06-19       Impact factor: 4.432

3.  Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors.

Authors:  A Butler; J M Hill; S J Ireland; C C Jordan; M B Tyers
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

4.  Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain.

Authors:  B Costall; A M Domeney; R J Naylor; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

5.  5-HT3 receptor antagonists block morphine- and nicotine-induced place-preference conditioning.

Authors:  E Carboni; E Acquas; P Leone; L Perezzani; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1988-06-22       Impact factor: 4.432

6.  Activation of a 5-HT3 receptor releases dopamine from rat striatal slice.

Authors:  P Blandina; J Goldfarb; J P Green
Journal:  Eur J Pharmacol       Date:  1988-10-18       Impact factor: 4.432

7.  Quasi morphine-abstinence syndrome.

Authors:  H O Collier; D L Francis; G Henderson; C Schneider
Journal:  Nature       Date:  1974-05-31       Impact factor: 49.962

8.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.

Authors:  P B Bradley; G Engel; W Feniuk; J R Fozard; P P Humphrey; D N Middlemiss; E J Mylecharane; B P Richardson; P R Saxena
Journal:  Neuropharmacology       Date:  1986-06       Impact factor: 5.250

10.  Heroin reward is dependent on a dopaminergic substrate.

Authors:  M A Bozarth; R A Wise
Journal:  Life Sci       Date:  1981-11-02       Impact factor: 5.037

View more
  5 in total

1.  Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.

Authors:  Larry F Chu; Tom Rico; Erika Cornell; Hannah Obasi; Ellen M Encisco; Haley Vertelney; Jamison G Gamble; Clayton W Crawford; John Sun; Anna Clemenson; Matthew J Erlendson; Robin Okada; Ian Carroll; J David Clark
Journal:  Drug Alcohol Depend       Date:  2017-08-14       Impact factor: 4.492

2.  Chronic morphine drinking establishes morphine tolerance, but not addiction in Wistar rats.

Authors:  Ralf Binsack; Ming-lan Zheng; Zhan-sai Zhang; Liu Yang; Yong-ping Zhu
Journal:  J Zhejiang Univ Sci B       Date:  2006-11       Impact factor: 3.066

3.  5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice.

Authors:  De-Yong Liang; XiangQi Li; J David Clark
Journal:  Anesthesiology       Date:  2011-05       Impact factor: 7.892

4.  Sleep Deprivation-Induced Blood-Brain Barrier Breakdown and Brain Dysfunction are Exacerbated by Size-Related Exposure to Ag and Cu Nanoparticles. Neuroprotective Effects of a 5-HT3 Receptor Antagonist Ondansetron.

Authors:  Aruna Sharma; Dafin F Muresanu; José V Lafuente; Ranjana Patnaik; Z Ryan Tian; Anca D Buzoianu; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2015-07-02       Impact factor: 5.590

5.  From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics.

Authors:  Larry F Chu; De-Yong Liang; Xiangqi Li; Peyman Sahbaie; Nicole D'arcy; Guochun Liao; Gary Peltz; J David Clark
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.